Responses
Oral Presentations
Still’s disease
OP0136 Baseline Characteristics of Patients with Active Systemic JIA Successfully Discontinuing Corticosteroid while Receiving Canakinumab: Secondary Analysis from a Pivotal Phase 3 Trial
Compose a Response to This Article
Other responses
No responses have been published for this article.